Risedronate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Risedronate

Clinical data
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	M05BA07 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	0.63%
Protein binding	~24%
Metabolism	None
Elimination half-life	1.5 hours
Excretion	Renal and fecal
Identifiers
IUPAC name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
CAS Number	105462-24-6
PubChem CID	5245
DrugBank	APRD00410
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C7H11NO7P2
Molar mass	283.112 g/mol
3D model (JSmol)	Interactive image
SMILES OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O

WikiDoc Resources for Risedronate
Articles
Most recent articles on Risedronate Most cited articles on Risedronate Review articles on Risedronate Articles on Risedronate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Risedronate Images of Risedronate Photos of Risedronate Podcasts & MP3s on Risedronate Videos on Risedronate
Evidence Based Medicine
Cochrane Collaboration on Risedronate Bandolier on Risedronate TRIP on Risedronate
Clinical Trials
Ongoing Trials on Risedronate at Clinical Trials.gov Trial results on Risedronate Clinical Trials on Risedronate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Risedronate NICE Guidance on Risedronate NHS PRODIGY Guidance FDA on Risedronate CDC on Risedronate
Books
Books on Risedronate
News
Risedronate in the news Be alerted to news on Risedronate News trends on Risedronate
Commentary
Blogs on Risedronate
Definitions
Definitions of Risedronate
Patient Resources / Community
Patient resources on Risedronate Discussion groups on Risedronate Patient Handouts on Risedronate Directions to Hospitals Treating Risedronate Risk calculators and risk factors for Risedronate
Healthcare Provider Resources
Symptoms of Risedronate Causes & Risk Factors for Risedronate Diagnostic studies for Risedronate Treatment of Risedronate
Continuing Medical Education (CME)
CME Programs on Risedronate
International
Risedronate en Espanol Risedronate en Francais
Business
Risedronate in the Marketplace Patents on Risedronate
Experimental / Informatics
List of terms related to Risedronate

For patient information, click here

Risedronate sodium (Actonel®) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Procter & Gamble and Sanofi-Aventis.

Administration

Risedronate is taken orally, usually 5 mg daily or 35 mg weekly. Notably, if risedronate lodges in the esophagus, it can lead to esophageal ulcers. Therefore, it is recommended that risedronate be taken with the body upright, and followed by a glass of water. Moreover, risedronate is poorly absorbed when taken with food, so it is recommended that no food or drink other than water be taken for 2 hours before and 30 minutes after taking risedronate. Risedronate has a faster esophageal transit time and different chemical chain which results in less gastrointestinal side-effects than other drugs in this class. The dosage instructions also show that risedronate can be taken with less water than other drugs in the class.

Controversies

In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva. The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on on September 7 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".

In 2006 P&G faced controversy over its handling of clinical research involving risedronate (News Reports and discussion).

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by a dental procedures.

References

Template:WikiDoc Sources